Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Merck & Co., Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

RAHWAY, N.J.--(BUSINESS WIRE)--MERCK (NYSE: MRK), KNOWN AS MSD OUTSIDE THE UNITED STATES AND CANADA, TODAY ANNOUNCED POSITIVE TOPLINE RESULTS FROM THE PHASE 3 KEYNOTE-905 TRIAL (ALSO KNOWN AS EV-303) IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER (MIBC) WHO ARE INELIGIBLE FOR CISPLATIN-BASED CHEMOTHERAPY. IN THIS STUDY, KEYTRUDA (PEMBROLIZUMAB) PLUS PADCEV (ENFORTUMAB VEDOTIN-EJFV), GIVEN BEFORE AND AFTER SURGERY (RADICAL CYSTECTOMY), DEMONSTRATED A STATISTICALLY SIGNIFICANT AND CLINICALLY ME.

KEYTRUDA (PEMBROLIZUMAB) PLUS PADCEV (ENFORTUMAB VEDOTIN-EJFV) SIGNIFICANTLY IMPROVED EVENT-FREE AND OVERALL SURVIVAL AND PATHOLOGIC COMPLETE RESPONSE RATE FOR CERTAIN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER WHEN GIVEN BEFORE AND AFTER SURGERY

RAHWAY, N.J.--(BUSINESS WIRE)--MERCK & CO., INC., RAHWAY, N.J., USA ANNOUNCES SECOND-QUARTER 2025 FINANCIAL RESULTS.

MERCK & CO., INC., RAHWAY, N.J., USA ANNOUNCES SECOND-QUARTER 2025 FINANCIAL RESULTS

THE U.S. KEYTRUDA MARKET, VALUED AT $17.87 BILLION IN 2024, FACES A PROJECTED CAGR DECLINE OF -3.12% BY 2033 DUE TO PATENT EXPIRATION AND BIOSIMILAR COMPETITION. KEYTRUDA'S CONTINUED USE IN VARIOUS CANCER TREATMENTS, INCLUDING MELANOMA AND LUNG CANCER, ALONGSIDE INNOVATIONS AND NEW TRIAL RESULTS, AIM TO MITIGATE THESE CHALLENGES AND SUSTAIN MARKET PRESENCE. THE U.S. KEYTRUDA MARKET, VALUED AT $17.87 BILLION IN 2024, FACES A PROJECTED CAGR DECLINE OF -3.12% BY 2033 DUE TO PATENT EXPIRATION AND BIOSIMILAR COMPETITION. KEYTRUDA'S CONTINUED USE IN VARIOUS CANCER TREATMENTS, INCLUDING MELANOMA AND LUNG CANCER, ALONGSIDE INNOVATIONS AND NEW TRIAL RESULTS, AIM TO MITIGATE THESE CHALLENGES AND SUSTAIN MARKET PRESENCE.

U.S. KEYTRUDA MARKET RESEARCH REPORT 2025 | MERCK'S KEYTRUDA FACES CHALLENGES AS PATENT EXPIRY APPROACHES IN 2028 - FORECAST TO 2033

RAHWAY, N.J.--(BUSINESS WIRE)--MERCK ANNOUNCES FOURTH-QUARTER 2025 DIVIDEND.

MERCK ANNOUNCES FOURTH-QUARTER 2025 DIVIDEND

DEEP APPLICATION PROVIDES FOUNDATION FOR COMMERCIAL EXECUTION PLEASANTON, CALIF. , JULY 21, 2025 /PRNEWSWIRE/ -- VEEVA SYSTEMS (NYSE: VEEV) TODAY ANNOUNCED THAT MERCK (NYSE: MRK), KNOWN AS MSD OUTSIDE OF THE UNITED STATES AND CANADA, HAS COMMITTED TO VEEVA VAULT CRM.

MERCK COMMITS TO VEEVA VAULT CRM

DISCOVER COMPREHENSIVE INSIGHTS WITH THE LIVESTOCK IDENTIFICATION MARKET COMPANIES QUADRANT. THIS ANALYSIS EVALUATES OVER 100 FIRMS, SPOTLIGHTING THE TOP 25 EVA FILMS LEADERS, FOCUSING ON KEY PLAYERS, PRODUCT INNOVATIONS, AND TECHNOLOGICAL TRENDS. LIVESTOCK IDENTIFICATION CRUCIALLY AIDS IN TRACKING, MANAGING, AND ENSURING ANIMAL HEALTH VIA TAGGING FOR PURPOSES LIKE DISEASE CONTROL AND TRADE COMPLIANCE. MARKET GROWTH IS FUELED BY AUTOMATION, IOT ADOPTION, AND DEMAND FOR REAL-TIME TRACKING. KEY PLAYERS LIKE MERCK & CO. AND SHEARWELL DATA EXCEL WITH ELECTRONIC AND VISUAL IDENTIFICATION PRODUCTS, WHILE OTHERS FOCUS ON ELECTRONIC SOLUTIONS. DISCOVER COMPREHENSIVE INSIGHTS WITH THE LIVESTOCK IDENTIFICATION MARKET COMPANIES QUADRANT. THIS ANALYSIS EVALUATES OVER 100 FIRMS, SPOTLIGHTING THE TOP 25 EVA FILMS LEADERS, FOCUSING ON KEY PLAYERS, PRODUCT INNOVATIONS, AND TECHNOLOGICAL TRENDS. LIVESTOCK IDENTIFICATION CRUCIALLY AIDS IN TRACKING, MANAGING, AND ENSURING ANIMAL HEALTH VIA TAGGING FOR PURPOSES LIKE DISEASE CONTROL AND TRADE COMPLIANCE. MARKET GROWTH IS FUELED BY AUTOMATION, IOT ADOPTION, AND DEMAND FOR REAL-TIME TRACKING. KEY PLAYERS LIKE MERCK & CO. AND SHEARWELL DATA EXCEL WITH ELECTRONIC AND VISUAL IDENTIFICATION PRODUCTS, WHILE OTHERS FOCUS ON ELECTRONIC SOLUTIONS.

LIVESTOCK IDENTIFICATION COMPANY EVALUATION REPORT 2025 | MERCK, SHEARWELL, DATAMARS DRIVE INNOVATIONS WITH COMPREHENSIVE TAGGING AND TRACKING SOLUTIONS

CAMBRIDGE, UK, 16 JULY 2025  AMPHISTA THERAPEUTICS (THE COMPANY OR AMPHISTA), A LEADER IN THE DISCOVERY OF NEXT-GENERATION, TARGETED PROTEIN DEGRADATION (TPD) MEDICINES, TODAY ANNOUNCES THE SUCCESSFUL ACHIEVEMENT OF ADISCOVERY RESEARCH MILESTONE UNDER ITS EXCLUSIVE RESEARCH COLLABORATION AND LICENCE AGREEMENT WITH MERCK. IN CONJUNCTION WITH THE MILESTONE ACHIEVEMENT, AMPHISTA RECEIVES A PRE-SPECIFIED FINANCIAL PAYMENT. THE ASSOCIATED TARGET ON WHICH THE MILESTONE IS TRIGGERED IS CURRENTLY UNDISCLOSED.

AMPHISTA THERAPEUTICS ANNOUNCES ACHIEVEMENT OF A RESEARCH MILESTONE IN ITS COLLABORATION WITH MERCK TRIGGERING A MILESTONE PAYMENT

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ. AND THE LAW FIRM OF KAHN SWICK & FOTI, LLC (KSF) ARE INVESTIGATING THE PROPOSED SALE OF VERONA PHARMA PLC (NASDAQGM: VRNA) TO MERCK & CO., INC. (NYSE: MRK). UNDER THE TERMS OF THE PROPOSED TRANSACTION, SHAREHOLDERS OF VERONA WILL RECEIVE $107.00 IN CASH FOR EACH SHARE OF AMERICAN DEPOSITORY SHARE THAT THEY OWN. KSF IS SEEKING TO DETERMINE WHETHER THIS CONSIDERATION AND THE PROCESS.

VERONA PHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF VERONA PHARMA PLC - VRNA

RAHWAY, N.J.--(BUSINESS WIRE)--MERCK ANIMAL HEALTH, KNOWN AS MSD ANIMAL HEALTH OUTSIDE OF THE UNITED STATES AND CANADA, A DIVISION OF MERCK & CO., INC., RAHWAY, N.J., USA (NYSE:MRK), TODAY ANNOUNCED THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL OF BRAVECTO QUANTUM (FLURALANER FOR EXTENDED-RELEASE INJECTABLE SUSPENSION)  A NEW, ONCE-YEARLY1 INJECTABLE PRODUCT TO TREAT AND PROTECT DOGS FROM FLEAS AND TICKS. THE PRODUCT IS EXPECTED TO BE AVAILABLE AT VETERINARY CLINICS AND HOSPITALS N.

FDA APPROVES BRAVECTO QUANTUM (FLURALANER FOR EXTENDED-RELEASE INJECTABLE SUSPENSION) FROM MERCK ANIMAL HEALTH

RAHWAY, N.J. & RALEIGH, N.C.--(BUSINESS WIRE)--MERCK (NYSE: MRK), KNOWN AS MSD OUTSIDE OF THE UNITED STATES AND CANADA, AND VERONA PHARMA PLC (NASDAQ: VRNA) (VERONA PHARMA), A BIOPHARMACEUTICAL COMPANY FOCUSED ON RESPIRATORY DISEASES, TODAY ANNOUNCED THAT THE COMPANIES HAVE ENTERED INTO A DEFINITIVE AGREEMENT UNDER WHICH MERCK, THROUGH A SUBSIDIARY, WILL ACQUIRE VERONA PHARMA FOR $107 PER AMERICAN DEPOSITORY SHARE (ADS), EACH OF WHICH REPRESENTS EIGHT VERONA PHARMA ORDINARY SHARES, FOR A TOTA.

MERCK TO ACQUIRE VERONA PHARMA, EXPANDING ITS PORTFOLIO TO INCLUDE OHTUVAYRE (ENSIFENTRINE), A FIRST-IN-CLASS COPD MAINTENANCE TREATMENT FOR ADULTS AND EXPECTED TO DRIVE GROWTH INTO THE NEXT DECADE

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--MERCK (NYSE: MRK), KNOWN AS MSD OUTSIDE OF THE UNITED STATES AND CANADA, ANNOUNCED TODAY THAT NEW DATA FROM ITS RESEARCH PIPELINE FOR HIV PREVENTION AND TREATMENT WILL BE PRESENTED AT THE 13TH INTERNATIONAL AIDS SOCIETY CONFERENCE ON HIV SCIENCE (IAS 2025) TAKING PLACE JULY 13-17, 2025, IN KIGALI, RWANDA. MERCK WILL SHARE NEW SCIENTIFIC FINDINGS FROM ITS HIV CLINICAL DEVELOPMENT PROGRAMS, INCLUDING PHASE 2 DATA ON THE SAFETY AND PHARMACOKINETICS OF MK-8527, AN INV.

MERCK TO PRESENT NEW DATA HIGHLIGHTING RESEARCH ADVANCEMENTS ACROSS ITS HIV PREVENTION AND TREATMENT PIPELINE AT IAS 2025

RAHWAY, N.J.--(BUSINESS WIRE)--MERCK (NYSE: MRK), KNOWN AS MSD OUTSIDE OF THE UNITED STATES AND CANADA, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS ACCEPTED AND GRANTED PRIORITY REVIEW FOR A NEW SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION (SBLA) SEEKING APPROVAL TO UPDATE THE U.S. PRODUCT LABEL BASED ON THE PHASE 3 ZENITH TRIAL FOR WINREVAIR (SOTATERCEPT-CSRK). IN 2024, WINREVAIR WAS APPROVED FOR THE TREATMENT OF ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH, GROUP 1.

FDA GRANTS PRIORITY REVIEW FOR WINREVAIR (SOTATERCEPT-CSRK) TO UPDATE LABEL BASED ON RESULTS FROM ZENITH TRIAL

DUBAI, UNITED ARAB EMIRATES--(BUSINESS WIRE)-- #CEO--MERCK FOUNDATION CONDUCTED THE 7TH EDITION OF MERCK FOUNDATION FIRST LADIES INITIATIVE - MFFLI SUMMIT 2025 IN DUBAI, UNITED ARAB EMIRATES.

MERCK FOUNDATION CHAIRMAN, CEO, AND 14 FIRST LADIES INAUGURATE THE 7TH EDITION OF MERCK FOUNDATION FIRST LADIES INITIATIVE - MFFLI SUMMIT IN DUBAI

RAHWAY, N.J.--(BUSINESS WIRE)--MERCK TO HOLD SECOND-QUARTER 2025 SALES AND EARNINGS CONFERENCE CALL JULY 29.

MERCK TO HOLD SECOND-QUARTER 2025 SALES AND EARNINGS CONFERENCE CALL JULY 29

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--ACIP RECOMMENDS MERCK'S ENFLONSIA FOR PREVENTION OF RSV IN INFANTS YOUNGER THAN 8 MONTHS OF AGE BORN DURING OR ENTERING THEIR FIRST RSV SEASON.

ACIP RECOMMENDS USE OF MERCK'S ENFLONSIA (CLESROVIMAB-CFOR) FOR PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) LOWER RESPIRATORY TRACT DISEASE IN INFANTS YOUNGER THAN 8 MONTHS OF AGE BORN DURING OR ENTERING THEIR FIRST RSV SEASON

RAHWAY, N.J.--(BUSINESS WIRE)--MERCK TO HOLD INVESTOR EVENT TO HIGHLIGHT ADVANCING RESEARCH PIPELINE FOR HIV TREATMENT AND PREVENTION.

MERCK TO HOLD INVESTOR EVENT TO HIGHLIGHT ADVANCING RESEARCH PIPELINE FOR HIV TREATMENT AND PREVENTION

RAHWAY, N.J.--(BUSINESS WIRE)--MERCK (NYSE: MRK), KNOWN AS MSD OUTSIDE OF THE UNITED STATES AND CANADA, TODAY ANNOUNCED POSITIVE TOPLINE RESULTS FROM THE PHASE 3 HYPERION STUDY EVALUATING WINREVAIR (SOTATERCEPT-CSRK) VERSUS PLACEBO (BOTH IN COMBINATION WITH BACKGROUND THERAPY) IN RECENTLY DIAGNOSED ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH, WHO* GROUP 1) FUNCTIONAL CLASS (FC) II OR III AT INTERMEDIATE OR HIGH RISK OF DISEASE PROGRESSION. HYPERION MET ITS PRIMARY ENDPOINT OF TIME TO CLIN.

MERCK ANNOUNCES PHASE 3 HYPERION STUDY OF WINREVAIR (SOTATERCEPT-CSRK) MET PRIMARY ENDPOINT IN RECENTLY DIAGNOSED ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH)

BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--THE FIRST PATIENT HAS BEEN DOSED IN THE IDEATE-PROSTATE01 PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF INVESTIGATIONAL IFINATAMAB DERUXTECAN (I-DXD) VERSUS DOCETAXEL IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WITH DISEASE PROGRESSION DURING OR AFTER TREATMENT WITH AN ANDROGEN RECEPTOR PATHWAY INHIBITOR. IFINATAMAB DERUXTECAN IS A SPECIFICALLY ENGINEERED, POTENTIAL FIRST-IN-CLASS B7-H3 DIRECTED DXD ANTIBODY.

Merck & Co., Inc.

MRK

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Merck & Co., Inc.

MRK.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

MRK